GEN Exclusives

More »

People in the News

More »
Jan 15, 2013 (Vol. 33, No. 2)

People in the News

  • Click Image To Enlarge +
    Henri Termeer

    Henri Termeer joined Prosensa as strategic advisor. Formerly, Termeer served as chairman, president, and CEO at Genzyme. He also served on the board of directors at Abiomed, Aveo Pharmaceuticals, and Massachusetts General Hospital, among others.

  •  

    Circassia appointed Jean-Jacques Garaud, M.D., to its board of directors...INC Research hired Robert Ryan, Ph.D., as vp of regulatory strategy, consulting, and submissions and Sal Chiovari as chief information officer...Valeant Pharmaceuticals named Ryan Weldon as evp of U.S. dermatology operations and Jason Hanson as evp of U.S. and international businesses...Charlie Morris joined Almac Clinical Technologies as vp of new products and services...The Vaccine and Gene Therapy Institute of Florida added Ted M. Ross, Ph.D., as program director.

     

  • Click Image To Enlarge +
    Kristine M. Ball

    Relypsa hired Kristine M. Ball as svp and CFO. Most recently, Ball was svp and CFO of KAI Pharmaceuticals. Prior to KAI, she served as vp of finance at Exelixis. Before joining Exelixis, Ball was a senior manager at Ernst & Young.

  •  

    Gil Ben-Menachem, Ph.D., is now CEO at OphthaliX...IntelliCell BioSciences added Harry Fisch, M.D., as director of urology...Sequenom named William Welch as president and COO, Dirk van den Boom as evp of R&D, and chief technology officer, and Ronald Lindsay as evp of strategic planning...Virginia Bio appointed Nee-Yin Chou, Ph.D., Alan Connor, Alex Euler, Frank Gilg, Jim Powers, Jason Walsh, and Kenneth Wong, Ph.D., to its board of directors...Bryan M. Reasons is now svp and CFO at Impax Laboratories.

     

  • Click Image To Enlarge +
    Stephen Hoge, M.D.

    Moderna Therapeutics added Stephen Hoge, M.D., as svp of corporate development and new drug concepts. Prior to Moderna, Dr. Hoge was a partner at McKinsey & Company and a leader in the firm’s global healthcare and corporate finance practices.

  •  

    A.P. Pharma hired Mark S. Gelder, M.D., as svp and CMO, Joel Schaedler as vp of market access, and Daniel Martin as vp of marketing...CytoDyn appointed Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., to its board of directors and Michael D. Mulholland as CFO, treasurer, and corporate secretary...Etubics named Gilbert S. Omenn, M.D., Ph.D., to its board of directors...Amgen appointed Robert A. Bradway as chairman of the board and Vance D. Coffman as lead independent director...Maurice Exner, Ph.D., joined IntelligentMDx as vp of research and development.

     

  • Click Image To Enlarge +
    Dalvir Gill, Ph.D.

    TransCelerate BioPharma elected Dalvir Gill, Ph.D., as CEO. Formerly, he was the president of Phase II–IV drug development at PharmaNet-i3. He also served as president of late-stage development, evp and COO, evp clinical research, and svp clinical operations.

  •  

    AtheroNova added Mark K. Wedel, M.D., as svp of clinical affairs and CMO...Third Rock Ventures hired Mark L. Perry and Uday N. Kumar, M.D., as entrepreneurs-in-residence...Oncology Analytics named Robert M. Walton as COO and to its board of directors.

     

  • Click Image To Enlarge +
    Mark Iwicki

    Blend Therapeutics added Mark Iwicki as president and CEO. Most recently, he was CEO of Sunovion Pharmaceuticals. Before that he was CCO of Sepracor. Prior to joining Sepracor, he was the svp and head of the cardiovascular business unit at Novartis Pharmaceuticals.

  •  

    Onyx Pharmaceuticals named N. Anthony Coles, M.D., as chairman of its board of directors...RF Technologies hired Sean Daugherty as svp and general manager for solutions development and sales...Omni Bio Pharmaceutical added Bruce E. Schneider, Ph.D., as CEO...AVEO Oncology appointed Robert Epstein, M.D., to its board of directors...Dale Schenk, Ph.D., is now CEO of Prothena...Icon elected Thomas Lynch as chairman...BioTime hired Jeffrey Janus as vp of sales and marketing.

     

  • Click Image To Enlarge +
    Joseph M. Limber

    XOMA appointed Joseph M. Limber to its board of directors. Limber is currently president and CEO of Prometheus Laboratories. Before joining Prometheus, he was a consultant and interim CEO at Deltagen. Previously, Limber was president and CEO of Aclara BioSciences.

  •  

    CorMedix promoted Randy Milby to CEO, Richard M. Cohen to CFO, and Antony E. Pfaffle, M.D., as acting CSO...iBio appointed of Seymour Flug to its board of directors and Andrea Corcoran as svp, finance and strategy...Christopher S. Destro joined Atossa Genetics as vp of sales and marketing...Helix BioPharma named John A. Rogers to its board of directors.

  • Send your People Announcements to sbhutta@genengnews.com


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?